Processed Transcript Insertion as a Novel Germline Mutational Mechanism in BRCA1-Associated Hereditary Breast Cancer
Open Access
Abstract
Background/Objectives: Germline BRCA1 mutations account for ~15–20% of hereditary breast and ovarian cancer (HBOC) cases. While most are small sequence variants, structural rearrangements also contribute significantly to the pathogenic landscape. Conventional diagnostic workflows often miss such events, underscoring the need for comprehensive approaches. Here, we report a previously undescribed pathogenic mechanism—a transposon-mediated processed transcript insertion—expanding the mutational spectrum underlying hereditary breast cancer susceptibility. Methods: The studied case was discovered during our germline genotyping routine: next-generation sequencing followed by library preparation with a custom hereditary cancer panel. The identified variant was validated by orthogonal sequencing and multiplex ligation-dependent probe amplification (MLPA). RNA-level functional assays, including nonsense-mediated decay inhibition, were conducted to assess transcript stability. Constitutional origin was confirmed by analysis of multiple normal tissues, and tumor material was evaluated for loss of heterozygosity (LOH). Results: NGS detected a 700 bp insertion in exon 16 of BRCA1, corresponding to a complete processed transcript of RPL18A. The insertion caused a frameshift and premature stop codon, triggering degradation of the aberrant transcript. The variant was present in multiple somatic tissues, and its heritable nature was further confirmed by genotyping a first-degree relative, who was also found to carry the insertion. Tumor DNA analysis revealed strong LOH with retention of the variant allele. Conclusions: This study identifies, for the first time, a heritable processed transcript insertion as a pathogenic event in BRCA1. Such variants are undetectable by conventional diagnostic workflows lacking structural variant analysis, highlighting the importance of comprehensive approaches for accurate diagnosis and genetic counselling in hereditary cancer syndromes.Keywords
Funding Information
- National Research, Development and Innovation Fund of the Ministry of Culture and Innovation (2022-2.1.1-NL-2022-00010)
- Hungarian Thematic Excellence Program (TKP2021-EGA-44)
- János Bolyai Postdoctoral Scholarship (BO/00141/21)
- New National Excellence Program Bolyai+ Scholarship (ÚNKP-23-5-SE-16)
- COST Action CA20122 Harmonization
- NRDI (NKFI-FK135065)
- New National Excellence Program of the Ministry of Human Capacities (ÚNKP-23-5-SE-4)
- Bolyai Research Fellowship of the Hungarian Academy of Sciences
This publication has 29 references indexed in Scilit:
- Spectrum and genotyping strategies of “dark” genetic matter in germline susceptibility genes of tumor syndromesCritical Reviews in Oncology/Hematology, 2024
- Identification of pathogenic retrotransposon insertions in cancer predisposition genesCancer Genetics, 2017
- Processed pseudogenes acquired somatically during cancer developmentNature Communications, 2014
- Deep intronicAPCmutations explain a substantial proportion of patients with familial or early-onset adenomatous polyposisHuman Mutation, 2012
- De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genesHuman Mutation, 2005
- Comparative analysis of processed pseudogenes in the mouse and human genomesTrends in Genetics, 2004
- Human LINE retrotransposons generate processed pseudogenesNature Genetics, 2000
- An estimated frequency of endogenous insertional mutations in humansNature Genetics, 1999
- The impact of L1 retrotransposons on the human genomeNature Genetics, 1998
- Human L1 Retrotransposon Encodes a Conserved Endonuclease Required for RetrotranspositionCell, 1996